



ASX/Media release

18 July 2007

AtCor announces pharmaceutical trial contract with new US client

- **Breaking scientific research, new European guidelines on central blood pressure to help fuel company growth**

AtCor Medical Holdings Limited (ASX:ACG), the developer and marketer of the SphygmoCor[®] system which measures central blood pressures and arterial stiffness non-invasively, today announced that it has signed a contract to supply SphygmoCor systems and clinical trial support services to a leading international pharmaceutical company, headquartered in the United States. The new contract brings to US\$1.8 million the total value of new contracts signed with pharmaceutical companies in the last 30 days.

“With this new contract, valued at US\$0.5 million, AtCor has acquired an additional US-based pharmaceutical client with international operations,” said Duncan Ross, AtCor Medical chief executive officer. Ross attributed strong pharmaceutical industry demand to increased awareness of the importance of monitoring central blood pressure in evaluating drug effects and assessing cardiovascular risk.

“A landmark event recently occurred,” Ross said. “For the first time the European Society of Hypertension and the European Society of Cardiology have issued guidelines highlighting what major studies such as CAFE have stated: non-invasive central blood pressure monitoring reveals effects of drug therapy that cannot be seen with conventional blood pressure monitoring at the arm.”

“AtCor is the pioneer and leading provider of non-invasive central blood pressure assessment technology in Europe, the US and Asia,” Ross stated. “At the recent American Society of Hypertension (ASH) annual meeting, over 30 scientific poster sessions that incorporated SphygmoCor monitoring were presented. Internationally, over 200 peer-reviewed scientific articles incorporating SphygmoCor monitoring have been published. This continuing flow of supportive new research, from scientists and clinicians around the world, is fueling the rapid growth of our clinical trials business.”

About AtCor

AtCor Medical develops and markets products for the early detection and management of cardiovascular disease, providing SphygmoCor systems to hospitals, clinics, research laboratories and for use in clinical trials. AtCor has operations in Australia, the United States, and Europe. AtCor is listed on the ASX under code ACG. For further information, please visit our web site at www.atcormedical.com.

For further information, please contact:

Duncan Ross – AtCor Medical CEO
+1 (630) 799 8221

Peter Manley – AtCor Medical CFO
+61 (2) 9874 8761

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au